Welte K - Search Results

1

Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.

Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL, et al. Kolitz JE, et al. Among authors: welte k. J Biol Response Mod. 1987 Aug;6(4):412-29. J Biol Response Mod. 1987. PMID: 3498011

2

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al. Kolitz JE, et al. Among authors: welte k. J Biol Response Mod. 1988 Oct;7(5):457-72. J Biol Response Mod. 1988. PMID: 3263471

3

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R. Chapman PB, et al. Among authors: welte k. Invest New Drugs. 1988 Sep;6(3):179-88. doi: 10.1007/BF00175395. Invest New Drugs. 1988. PMID: 3263958

4

Interleukin 2: a review.

Kolitz JE, Welte K, Sykora KW, Mertelsmann R. Kolitz JE, et al. Among authors: welte k. Arzneimittelforschung. 1985;35(10):1607-15. Arzneimittelforschung. 1985. PMID: 3000391 Review.

5

Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.

Bialas T, Kolitz J, Levi E, Polivka A, Oez S, Miller G, Welte K. Bialas T, et al. Among authors: welte k. Cancer Res. 1988 Feb 15;48(4):891-8. Cancer Res. 1988. PMID: 3257413

6

Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivo.

Atzpodien J, Gulati SC, Kwon JH, Kushner BH, Shimazaki C, Bührer C, Oz S, Kolitz JE, Welte K, Clarkson BD. Atzpodien J, et al. Among authors: welte k. Exp Cell Biol. 1988;56(5):236-44. doi: 10.1159/000163486. Exp Cell Biol. 1988. PMID: 3265922

7

Lymphokine-activated killer cells are generated before classical cytotoxic T lymphocytes after bone marrow transplantation in mice.

Merluzzi VJ, Savage DM, Smith MD, Last-Barney K, Mertelsmann R, Moore MA, Welte K. Merluzzi VJ, et al. Among authors: welte k. J Immunol. 1985 Sep;135(3):1702-6. J Immunol. 1985. PMID: 3894518

8

Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2.

Merluzzi VJ, Welte K, Savage DM, Last-Barney K, Mertelsmann R. Merluzzi VJ, et al. Among authors: welte k. J Immunol. 1983 Aug;131(2):806-9. J Immunol. 1983. PMID: 6134774

9

Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2.

Merluzzi VJ, Savage DM, Mertelsmann R, Welte K. Merluzzi VJ, et al. Among authors: welte k. Cell Immunol. 1984 Mar;84(1):74-84. doi: 10.1016/0008-8749(84)90078-9. Cell Immunol. 1984. PMID: 6199125

10

Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow.

Welte K, Keever CA, Levick J, Bonilla MA, Merluzzi VJ, Mertelsmann R, Evans R, O'Reilly RJ. Welte K, et al. Blood. 1987 Nov;70(5):1595-603. Blood. 1987. PMID: 3311208 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

386 results

Search Page

Filters